View in EDS HTML Full Text PDF Full Text

A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Saved in:
Bibliographic Details
Title: A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Authors: Graff JN; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA.; Division of Hematology and Oncology, VA Portland Health Care System, Portland, OR, USA., Smith CEP; Division of Hematology and Oncology, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA., Sokolova AO; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA., Qian DZ; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA., Beer TM; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA.; Division of Hematology and Oncology, VA Portland Health Care System, Portland, OR, USA., Latour E; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Bailey S; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA., Kreitner D; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA., Grivas P; Department of Medicine (Division Hematology/Oncology), University of Washington School of Medicine, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Schweizer MT; Department of Medicine (Division Hematology/Oncology), University of Washington School of Medicine, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Higano CS; Department of Medicine (Division Hematology/Oncology), University of Washington School of Medicine, Seattle, WA, USA., Alumkal JJ; Genitourinary Medical Oncology Section, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., Vuky J; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA., Yu EY; Department of Medicine (Division Hematology/Oncology), University of Washington School of Medicine, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Cheng HH; Department of Medicine (Division Hematology/Oncology), University of Washington School of Medicine, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Source: The oncologist [Oncologist] 2026 May 08; Vol. 31 (6).
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42112614
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Graff+JN%22">Graff JN</searchLink>; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA.; Division of Hematology and Oncology, VA Portland Health Care System, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Smith+CEP%22">Smith CEP</searchLink>; Division of Hematology and Oncology, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sokolova+AO%22">Sokolova AO</searchLink>; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Qian+DZ%22">Qian DZ</searchLink>; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Beer+TM%22">Beer TM</searchLink>; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA.; Division of Hematology and Oncology, VA Portland Health Care System, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Latour+E%22">Latour E</searchLink>; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Bailey+S%22">Bailey S</searchLink>; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Kreitner+D%22">Kreitner D</searchLink>; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Grivas+P%22">Grivas P</searchLink>; Department of Medicine (Division Hematology/Oncology), University of Washington School of Medicine, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Schweizer+MT%22">Schweizer MT</searchLink>; Department of Medicine (Division Hematology/Oncology), University of Washington School of Medicine, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Higano+CS%22">Higano CS</searchLink>; Department of Medicine (Division Hematology/Oncology), University of Washington School of Medicine, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Alumkal+JJ%22">Alumkal JJ</searchLink>; Genitourinary Medical Oncology Section, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.<br /><searchLink fieldCode="AU" term="%22Vuky+J%22">Vuky J</searchLink>; Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Yu+EY%22">Yu EY</searchLink>; Department of Medicine (Division Hematology/Oncology), University of Washington School of Medicine, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Cheng+HH%22">Cheng HH</searchLink>; Department of Medicine (Division Hematology/Oncology), University of Washington School of Medicine, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2026 May 08; Vol. 31 (6).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42112614
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/oncolo/oyag180
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Graff JN
      – PersonEntity:
          Name:
            NameFull: Smith CEP
      – PersonEntity:
          Name:
            NameFull: Sokolova AO
      – PersonEntity:
          Name:
            NameFull: Qian DZ
      – PersonEntity:
          Name:
            NameFull: Beer TM
      – PersonEntity:
          Name:
            NameFull: Latour E
      – PersonEntity:
          Name:
            NameFull: Bailey S
      – PersonEntity:
          Name:
            NameFull: Kreitner D
      – PersonEntity:
          Name:
            NameFull: Grivas P
      – PersonEntity:
          Name:
            NameFull: Schweizer MT
      – PersonEntity:
          Name:
            NameFull: Higano CS
      – PersonEntity:
          Name:
            NameFull: Alumkal JJ
      – PersonEntity:
          Name:
            NameFull: Vuky J
      – PersonEntity:
          Name:
            NameFull: Yu EY
      – PersonEntity:
          Name:
            NameFull: Cheng HH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 08
              M: 05
              Text: 2026 May 08
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1549-490X
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: The oncologist
              Type: main
ResultId 1